PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY

At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.